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Abstract 
BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneezing, 
rhinorrhea, nasal congestion and nasopharyngeal itching. Subcutaneous immunotherapy (SCIT) for specific 
allergens is an effective treatment and induces the inhibitory effect of T regulatory lymphocytes and decreases 
clinical symptoms in allergic rhinitis.  
AIM: In this study effect of subcutaneous immunotherapy with specific allergens on clinical symptoms and T 
regulatory and T Helper cells cytokines, in patients with allergic rhinitis are evaluated.  
METHODS: In this study, 30 patients with moderate to severe allergic rhinitis according to clinical criteria and 
positive skin prick test for aeroallergens were selected and treated by SCIT. Clinical symptoms and T cells 
cytokines IL4, IL17, IFN gamma, TGF beta, GITR, FOXP3 and IL-10 (by RT-PCR) were evaluated before and one 
year after initiation of treatment. 
RESULTS: Thirty (30) patients with allergic rhinitis at age range 15-45 years old were treated by SCIT, and 23 (14 
female, 9 male) patients continued the study, and 7 patients did not continue treatment. After immunotherapy, 
clinical symptoms decreased significantly. The specific cytokines TGF beta and IL10 levels increased and 
changes were statistically significant. (Respectively P = 0.013 and P = 0.05) The IL17 level was also increased, 
but not statistically significant. (P = 0.8) IFN gamma, IL4, GITR, FOXP3, all decreased, but the changes were not 
statistically significant (P > 0.05). 
CONCLUSION: Subcutaneous Immunotherapy for specific allergens decreases clinical symptoms in patients with 
allergic rhinitis and induces tolerance in T lymphocytes, especially by increasing T regulatory cells cytokines, TGF 
beta and IL10. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Allergic rhinitis (AR) is one of the most 
common types of allergy worldwide. Recent studies 
have shown an increase in its prevalence during 
recent decades ranging from 1.4 to 45%. Allergic 
rhinitis has direct and indirect effects on the quality of 
life and is accompanied by a group of another disease 
including asthma, middle ear inflammation, nasal 
polyps, sinusitis and lower respiratory tract infections 
[1] [2]. 
The diagnosis of AR is made based on clinical 
symptoms such as sneezing, rhinorrhea, itchy nose 
and nasal congestion when there is no sign of lower 
respiratory tract infections or anatomic abnormalities 
of the nose. Also when lab findings including a 
positive prick test and IgE specific antibody are in 
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favour of allergy, regarding the patients’ history and 
clinical examination [3] [4]. 
The treatment of allergic rhinitis initially 
includes the avoidance of allergens especially 
common inhaled allergens. Indoor allergens such as 
house dust mites (HDM) especially in bed and house 
fungi which grow in damp places besides pets, indoor 
plants, grass, trees and grass pollen and other 
allergenic plants should also be avoided [1] [3] [4] [5]. 
Also, certain medications such as oral antihistamines, 
topical decongestants, inhaled corticosteroids and in 
certain cases oral corticosteroids are prescribed [1] [3] 
[5]. Immunotherapy with allergens is a therapeutic 
method in which the allergen is gradually and with an 
incremental dose administered resulting in the 
alleviation of clinical symptoms and reduced disease 
severity while preventing disease progression [1] [5] 
[6].  
Immunotherapy with allergens has proven 
efficacy in the treatment of allergic rhinitis/ asthma 
and allergy to insect sting [1]. Today, subcutaneous 
injection of an allergen (SCIT) is the most common 
type of immunotherapy. Several studies have shown 
desirable clinical efficacy in the single and combined 
administration of allergens [1] [7] [8]. In different 
studies immunotherapy has resulted in a decrease in 
the number of principal cells in allergic responses 
(eosinophils/basophils and mast cells) and an 
increase in IgG4; moreover changes in lymphocytes 
including a rise in CD8+ and Treg cells and a 
decrease in IL4 and IL5 levels has been observed [1] 
[4] [6]. 
It seems that immunotherapy has a major role 
in the induction of specific Treg cells and that the 
induction of tolerance in T lymphocytes is the base of 
immunotherapy. The tolerance of peripheral T 
lymphocytes is recognised by the production of 
allergen-specific Treg cells. In addition to tolerance 
induction, immunotherapy prevents sensitisation 
towards new allergens and allergy progression 
[3][9][10]. CD4+ Treg-cells are divided into two 
categories: Natural Treg (nTreg) and Inducible Treg 
(iTreg) cells. Each of these subsets has a specific 
marker and express their specific receptors which for 
nTreg cells include CCR4/GITR/CTLA4/CD62L and 
for iTreg cells include IL10/TGF-beta. Natural Treg 
cells react to autoantibodies which are expressed in 
the thymus whereas Inducable Treg cells react 
towards peripheral antigens which are expressed by 
dendritic cells [1] [11] [12]. 
The nTreg cells originating from the thymus 
express an intracellular marker named FOXP3. It has 
been proved that following immunotherapy, the 
presence of FOXP3+ cells is increased in the nasal 
mucosa and this increase is consistent with the 
improvement of allergic rhinitis [4] [12]. 
The present study aimed at evaluating the 
effect of immunotherapy on the clinical symptoms and 
cytokine changes related to T lymphocytes in 
moderate to severe AR patients. 
 
 
Methods 
 
The present study is an experimental 
interventional trial which investigates the effect of 
immunotherapy on the clinical symptoms and the 
immune system of patients with moderate to severe 
perennial AR in Ghaem Hospital, Mashhad, IRAN 
during October 2008 to October 2009. A full medical 
history was initially taken from patients with perennial 
AR, and a thorough physical examination was 
performed. Prick test with the standard method and by 
using the common regional aeroallergens was 
performed with 6 extracts (Hollister, USA) to confirm 
the basis of allergy. In the mentioned test more than 
3mm induration from the negative control was 
regarded as a positive test result. 
The used tools were the following:  
1. A structured questionnaire according to the 
AR scoring system 
2. Skin scratch testing according to the 
European Academy of Allergy and Clinical 
Immunology 
3. Allergenic extracts used for cluster 
immunotherapy 
The inclusion criteria were typical signs of AR 
in exposure with inhaled allergens, positive results in 
the standard questionnaire, and a positive skin prick 
test with at least 3 standard inhaled allergen extracts. 
Patients were excluded in case of consuming beta 
blockers, accompanying uncontrolled asthma, and 
concomitant conditions including autoimmune 
disease, psychotic disorders, pregnancy and other 
forms of rhinitis. For lab studies 5-7 cc blood was 
taken from the brachial vein and lymphocyte markers 
regarding the phenotype of TH1, TH2 TH17 and Treg 
and specific markers of GITR, FOXP3, IFN-γ, IL17, 
IL10, IL4, TGFβ were evaluated with RNA extraction, 
cDNA production and eventually RT-PCR with the 
standard method (TaqMan for FOXP3 and cyber 
green for other cases). 
For patients with allergic rhinitis who received 
a minimum of immunotherapy to treat pollen allergies 
using Allergovit (composition: 015 grass/cereals-
100%; or composition: 108 Birch-35%, 115 Alder-
30%, 129 Hazel-35%, Allergopharma, Reinbek, 
Germany). 
The sample size was calculated as 25 cases 
concerning similar studies. Immunotherapy based on 
a planned schedule was conducted by the 
subcutaneous injection of mixed inhaled allergens 
extracts (Hollister, USA) with a concentration of 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1250                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
1:1000 of the original vial each week for 10 sessions, 
1:100 every two weeks for 10 sessions and finally 
1:10 monthly for one year. After a year after 
immunotherapy initiation, clinical and laboratory 
findings were once again evaluated. Wilcoxon test 
was used for IFN-γ, IL17 and IL10 measurements 
analysis whereas Paired T-test and the SPSS 
software version 11 were used for FOXP3, GITR, 
TGFβ, and IL4 measurements. 
The study protocol was approved by the 
Research Council of Mashhad University of Medical 
Sciences and written informed consent was obtained 
from each participant before study entry. 
 
 
Results  
 
Thirty patients with the diagnosis of allergic 
rhinitis underwent immunotherapy for one year. 
Twenty three (23) individuals, 9 males and 14 
females, completed the study. Seven patients did not 
consent to continue treatment. The participants’ age 
ranged from 15 to 45 years, and most patients 
experienced significant improvement in their clinical 
symptoms after the treatment period. Based on the 
clinical indices of TNS and TSS, disease severity was 
highest in the 30 to 39-year age group whereas the 
best therapeutic response was achieved in the 30 to 
34-year age group (Figure 1).  
 
Figure 1: Response to immunotherapy after one year according to 
age 
 
Regarding sex and response to 
immunotherapy; no meaningful response was 
obtained (P = 0.7). Considering the studied variables 
a year after treatment, an increase in the IL17 level 
was detected which was not statistically significant (P 
= 0.81). IFN-γ levels showed a reduction but with no 
meaningful significance (P = 0.21). However, the rise 
in TGB and IL10 levels was statistically significant, (P 
= 0.013, P = 0.05). Finally, a decrease in the level of 
IL4, GITR, FOXP3 was obtained, none showing a 
statistical significance (P > 0.05) (Figure 2). 
 
Figure 2: Expression of Cytokines before and after treatment 
 
 
 
Discussion 
 
Immunotherapy if performed in an appropriate 
way in the right patient will be a safe and effective 
treatment that not only prevents the symptoms but will 
also result in reduced disease severity beside 
preventing disease progression [3] [6] [13]. 
Immunotherapy with allergens is a slow-process 
treatment which alters the immunologic mechanisms 
of disease. Meta-analysis of the performed studies 
comparing the therapeutic effects of subcutaneous 
immunotherapy with medical therapy has shown that 
immunotherapy has equal effects on medical therapy 
and can even be considered at treatment initiation 
[14]. The induction of tolerance in peripheral T 
lymphocytes resulting in a change in the immune 
system pathway from TH2 to Treg cells is the main 
goal in immunotherapy which is accompanied by 
elevated IL10 and TGF beta levels [4]. Eventually, the 
production of IL10 will lead to the inhibition of 
allergen-specific IgE production and on the other hand 
will result in IgG4 production [15]. Although at the start 
of immunotherapy a transient rise in the allergen-
specific IgE level is observed, subsequently a gradual 
decrease takes place in the specific IgE level over 
years which prevents the rise of IgE in the mating 
season of plants in such patients [4]. 
 In recent studies, it has been reported that 
the blocking effects of IgG in immunotherapy are FCR 
IIB receptor-mediated [16] [17] [18]. Attention should 
be paid to the fact that IgG4 immunoglobulin levels 
decrease the following immunotherapy, but their 
protective and biologic effects remain constant [15]. 
Nevertheless, IL10 can reduce the release of 
pro-inflammatory cytokines from mastocytes. Also, 
IL10 can reduce the function and activity of basophils 
and suppress IL5 production by TH0 and TH2 
lymphocytes [9] [16] [18]. 
 Kouzegaran et al. Immunotherapy in Allergic Rhinitis: It’s Effect on the Immune System 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Jul 20; 6(7):1248-1252.                                                                                                                                                    1251 
 
Cezmi et al. studied the therapeutic 
mechanisms of Treg cells in immunotherapy and 
published their results in 2009 in JACI. They stated 
that an increase in the number of Treg, CD25+ and 
CD4+ cells in allergen-specific immunotherapy (SIT) 
has a significant role and that immunotherapy with the 
grass group will result in increased IL10 and TGF-β 
expression in T cells and the mucosa. 
One of the main characteristics of Treg cells 
is the expression of FOXP3 in them. In case of 
receiving signals from pro-inflammatory cytokines 
such as IL6, the FOXP3 function is inhibited, and the 
TH17 pathway is activated. For the induction of both 
the Treg and TH17 cells, TGF-β is required; but the 
function of these two cell groups are at odds with each 
other [19]. Although FOXP3 is expressed to a lesser 
degree by T-effector cells, the amount is very small, 
and it is expressed transiently; therefore FOXP3 is 
considered as a specific marker for Treg cells only 
[13] [15]. 
Bacchetta reported the principle role of Treg 
expressed FOXP3 as tolerance induction and 
prevention of effector T cell responses. In the 
mentioned study those Treg cells originating from the 
thymus were named as nT-reg cells, and those 
forming outside the thymus were called aT-reg 
(adaptive) cells [15] [17]. 
nT-reg cells react toward self-antigens 
expressed in the thymus whereas nT-reg or iT-reg 
cells including Trl (producing IL10) and TH3 
(producing TGFB) result from the differentiation of 
naive T cells following antigenic stimulation in the 
environment. In several studies, it has been proved 
that the number of CD4+CD25+FOXP3+ cells 
increases in the nasal mucosa following 
immunotherapy, inconsistent with the improvement of 
the symptoms of allergic rhinitis [10]. 
The deviation of allergen-specific effector 
cells towards the Treg phenotype is the key to 
successful immunotherapy even in healthy individuals’ 
immune responses. The inhibitory effect of IL10, 
known as an inhibitory cytokine for T cells, has been 
well proved in inducing tolerance towards allergens, 
autoantigens, bonding antigens and tumoral antigens. 
In 2009 Ciprandi et al., from Italy evaluated the TGF-β 
and IL17 levels in 23 allergic rhinitis patients before 
and after immunotherapy. TGF-β was 12.503 ± 
23.354 ng/ml and 43.305 ± 31.861 ng/ml before and 
after immunotherapy, respectively, (P = 0.0016). This 
study showed a remarkable rise in TGF-β levels one 
year after immunotherapy. It also confirmed a rise in 
IL10 following immunotherapy [5].  
Recently SLIT (sublingual immunotherapy) 
has found its place in immunotherapy. In a study by L. 
Cosmi et al., on the effects of SLIT in allergic rhinitis 
patients and mite-sensitive asthma, immunologic 
changes included reduced allergen-specific IgE and 
increased TGF-β, IL10 and IFN-γ levels [20]. In a 
study by Jutel et al., in 2003 in Switzerland, the 
mechanism of immunotherapy was studied in HDM-
sensitive patients after 70 days of immunotherapy. In 
a part of this study, the IL10 and TGF-β receptors 
were blocked and re-evaluated. Eventually, it was 
observed that the inhibitory responses of T-cells by 
IL10 and TGF-β are the key mechanism of the 
mucosal immune response to allergens. Also, the 
inhibitory effects of IL10 on T-lymphocytes were due 
to changes in the CD28 mediated signalling pathway 
while the inhibitory effects of TGF-β were due to its 
inhibitory effect on TCR/CD3 and the inhibition of the 
CD28 pathway. Moreover, IL15 which is one of the 
main factors in the survival and growth of T-cells is 
inhibited by IL10 and TGF-β [7]. 
In our study, a significant decrease was 
observed in the clinical symptoms of allergic rhinitis 
patients after immunotherapy. In lab studies similar to 
Cezmi and Ciprandi studies, a rise in TGF-β and IL10 
was detected in our patients. However, in contrast to 
previous studies, the FOXP3 was reduced although 
not to a significant level. Moreover, an increase in 
IL17 was detected following immunotherapy which 
could be suggestive of TH17 induction by TGF-β 
following the increase in this inhibitory factor. 
Regarding the obtained results from this 
study, it seems that the immunologic mechanism 
leading to the alleviation and improvement of 
symptoms in AR patients mainly includes a rise in the 
number of inducible Treg cells accompanied by 
increased TGF-β and IL10 levels. 
Limitation of the study: The limitation of the 
current study was small sample size because only 30 
patients had inclusion criteria. 
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